MedTrace Logo

Study of XIAP Antisense Given With Chemotherapy for Refractory/Relapsed AML

NCT00363974 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2009-12-01

No results posted yet for this study

Summary

The purpose of this study is to determine if the drug, called AEG35156, can be safely given to AML patients and whether it effectively reduces levels of a protein (XIAP) to increase the sensitivity of cancer cells to chemotherapy (ara-C and idarubicin) in patients with refractory or relapsed AML.

Conditions

  • Leukemia, Myelomonocytic, Acute

Interventions

DRUG

XIAP antisense

2 days loading dose followed by weekly 2hr infusion

Sponsors & Collaborators

  • Aegera Therapeutics

    lead INDUSTRY

Principal Investigators

  • Jacques Jolivet, MD · Aegera Therapeutics Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2009-03-31
Completion
2009-03-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00363974 on ClinicalTrials.gov